For patients with breast cancer, double mastectomy does not reduce mortality
the ONA take:
According to a new study published in The Journal of the American Medical Association, despite an increase in the number of women undergoing a double mastectomy for early-stage breast cancer, the procedure does not reduce the risk of mortality compared with breast-conserving therapy with radiation.
In the study, researchers identified 189,734 women diagnosed with early-stage unilateral breast cancer between 1998 and 2011 from the California Cancer Registry. Researchers followed the patients for an average of approximately 89 months.
They found that the rate of women with early-stage breast cancer undergoing double mastectomies rose from 2% to 12.3% in 1998 and 2011, respectively. Women aged 40 and over opting for the procedure rose from 3.6% to 33% in 1998 and 2011, respectively, making this group have the highest increase. Furthermore, the rate of women undergoing unilateral mastectomies decreased during this period.
In addition, the team found that women who chose to undergo a double mastectomy did not have a lower risk of mortality compared with women who underwent breast-conserving therapy plus radiation. Women who underwent a unilateral mastectomy were found to have a higher risk of death.
The procedure does not reduce the risk of mortality.
Having a double mastectomy for early-stage breast cancer is not linked to a lower risk of death than breast-conserving therapy plus radiation, but still there is an increase in the number of women undergoing the procedure. These are the findings of a new study published in JAMA.
This is not the first study to question the benefits of a double mastectomy, or bilateral mastectomy - the removal of both breasts - for breast cancer patients. Earlier this year, Medical News Today reported on a study published in JAMA Surgery claiming the procedure is unnecessary for the majority of women.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|